vs
Anika Therapeutics, Inc.（ANIK）とMERIT MEDICAL SYSTEMS INC（MMSI）の財務データ比較。上の社名をクリックして会社を切り替えられます
MERIT MEDICAL SYSTEMS INCの直近四半期売上が大きい（$393.9M vs $30.6M、Anika Therapeutics, Inc.の約12.9倍）。MERIT MEDICAL SYSTEMS INCの純利益率が高く（9.6% vs 1.0%、差は8.7%）。MERIT MEDICAL SYSTEMS INCの前年同期比売上増加率が高い（10.9% vs 0.0%）。MERIT MEDICAL SYSTEMS INCの直近四半期フリーキャッシュフローが多い（$74.0M vs $4.0M）。過去8四半期でMERIT MEDICAL SYSTEMS INCの売上複合成長率が高い（10.3% vs 2.7%）
メリットメディカルシステムズ社はグローバルな医療機器メーカーで、心臓病学、放射線学、腫瘍学、内視鏡検査、救命救護の各分野で使用される介入・診断用製品を開発・製造・販売しています。世界中の病院や医療機関に低侵襲のソリューションを提供し、患者の予後改善と診療効率の向上を支援しています。
ANIK vs MMSI — 直接比較
売上が大きい
MMSI
12.9倍大きい
$30.6M
売上成長率が高い
MMSI
+10.9%の差
0.0%
純利益率が高い
MMSI
純利益率が8.7%高い
1.0%
フリーキャッシュフローが多い
MMSI
FCF $70.1M多い
$4.0M
2年売上CAGRが高い
MMSI
2年複合成長率
2.7%
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $30.6M | $393.9M |
| 純利益 | $292.0K | $38.0M |
| 粗利率 | 62.6% | 49.6% |
| 営業利益率 | 2.1% | 13.8% |
| 純利益率 | 1.0% | 9.6% |
| 売上前年比 | 0.0% | 10.9% |
| 純利益前年比 | 101.3% | 36.0% |
| EPS（希薄化後） | $0.02 | $0.64 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ANIKMMSI
| Q4 25 | $30.6M | $393.9M | ||
| Q3 25 | $27.8M | $384.2M | ||
| Q2 25 | $28.2M | $382.5M | ||
| Q1 25 | $26.2M | $355.4M | ||
| Q4 24 | $30.6M | $355.2M | ||
| Q3 24 | $29.6M | $339.8M | ||
| Q2 24 | $30.7M | $338.0M | ||
| Q1 24 | $29.0M | $323.5M |
純利益ANIKMMSI
| Q4 25 | $292.0K | $38.0M | ||
| Q3 25 | $-2.3M | $27.8M | ||
| Q2 25 | $-4.0M | $32.6M | ||
| Q1 25 | $-4.9M | $30.1M | ||
| Q4 24 | $-21.9M | $27.9M | ||
| Q3 24 | $-29.9M | $28.4M | ||
| Q2 24 | $-88.0K | $35.7M | ||
| Q1 24 | $-4.5M | $28.2M |
粗利率ANIKMMSI
| Q4 25 | 62.6% | 49.6% | ||
| Q3 25 | 56.0% | 48.5% | ||
| Q2 25 | 50.9% | 48.2% | ||
| Q1 25 | 56.1% | 48.4% | ||
| Q4 24 | 56.0% | 48.7% | ||
| Q3 24 | 65.7% | 46.4% | ||
| Q2 24 | 66.7% | 47.7% | ||
| Q1 24 | 65.4% | 46.9% |
営業利益率ANIKMMSI
| Q4 25 | 2.1% | 13.8% | ||
| Q3 25 | -11.6% | 11.1% | ||
| Q2 25 | -14.8% | 12.3% | ||
| Q1 25 | -16.4% | 11.5% | ||
| Q4 24 | -2.3% | 10.3% | ||
| Q3 24 | -0.3% | 11.0% | ||
| Q2 24 | -5.9% | 13.6% | ||
| Q1 24 | -8.6% | 11.1% |
純利益率ANIKMMSI
| Q4 25 | 1.0% | 9.6% | ||
| Q3 25 | -8.4% | 7.2% | ||
| Q2 25 | -14.1% | 8.5% | ||
| Q1 25 | -18.6% | 8.5% | ||
| Q4 24 | -71.4% | 7.9% | ||
| Q3 24 | -101.2% | 8.4% | ||
| Q2 24 | -0.3% | 10.6% | ||
| Q1 24 | -15.6% | 8.7% |
EPS（希薄化後）ANIKMMSI
| Q4 25 | $0.02 | $0.64 | ||
| Q3 25 | $-0.16 | $0.46 | ||
| Q2 25 | $-0.28 | $0.54 | ||
| Q1 25 | $-0.34 | $0.49 | ||
| Q4 24 | $-1.49 | $0.46 | ||
| Q3 24 | $-2.03 | $0.48 | ||
| Q2 24 | $0.00 | $0.61 | ||
| Q1 24 | $-0.31 | $0.48 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $81.2M | $446.4M |
| 総負債低いほど良い | — | $734.0M |
| 株主資本純資産 | $143.5M | $1.6B |
| 総資産 | $190.3M | $2.7B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.46× |
8四半期トレンド — 暦四半期で整列
現金・短期投資ANIKMMSI
| Q4 25 | $81.2M | $446.4M | ||
| Q3 25 | $80.2M | $392.5M | ||
| Q2 25 | $77.1M | $341.8M | ||
| Q1 25 | $75.4M | $395.5M | ||
| Q4 24 | $79.2M | $376.7M | ||
| Q3 24 | $90.7M | $523.1M | ||
| Q2 24 | $96.6M | $636.7M | ||
| Q1 24 | $100.7M | $581.9M |
総負債ANIKMMSI
| Q4 25 | — | $734.0M | ||
| Q3 25 | — | $732.9M | ||
| Q2 25 | — | $731.8M | ||
| Q1 25 | — | $730.7M | ||
| Q4 24 | — | $729.6M | ||
| Q3 24 | — | $750.5M | ||
| Q2 24 | — | $801.3M | ||
| Q1 24 | — | $800.1M |
株主資本ANIKMMSI
| Q4 25 | $143.5M | $1.6B | ||
| Q3 25 | $146.8M | $1.5B | ||
| Q2 25 | $147.7M | $1.5B | ||
| Q1 25 | $148.4M | $1.4B | ||
| Q4 24 | $154.0M | $1.4B | ||
| Q3 24 | $179.9M | $1.3B | ||
| Q2 24 | $210.3M | $1.3B | ||
| Q1 24 | $208.5M | $1.2B |
総資産ANIKMMSI
| Q4 25 | $190.3M | $2.7B | ||
| Q3 25 | $189.4M | $2.6B | ||
| Q2 25 | $187.7M | $2.6B | ||
| Q1 25 | $190.6M | $2.5B | ||
| Q4 24 | $202.7M | $2.4B | ||
| Q3 24 | $231.4M | $2.4B | ||
| Q2 24 | $262.7M | $2.4B | ||
| Q1 24 | $263.7M | $2.3B |
負債/資本比率ANIKMMSI
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.65× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $4.6M | $98.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $4.0M | $74.0M |
| FCFマージンFCF / 売上 | 13.0% | 18.8% |
| 設備投資強度設備投資 / 売上 | 2.1% | 6.2% |
| キャッシュ転換率営業CF / 純利益 | 15.88× | 2.59× |
| 直近12ヶ月FCF直近4四半期 | $4.4M | $215.7M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローANIKMMSI
| Q4 25 | $4.6M | $98.5M | ||
| Q3 25 | $6.9M | $75.0M | ||
| Q2 25 | $-189.0K | $83.3M | ||
| Q1 25 | $-130.0K | $40.6M | ||
| Q4 24 | $1.6M | $68.7M | ||
| Q3 24 | $5.0M | $47.3M | ||
| Q2 24 | $-1.1M | $68.5M | ||
| Q1 24 | $-126.0K | $36.2M |
フリーキャッシュフローANIKMMSI
| Q4 25 | $4.0M | $74.0M | ||
| Q3 25 | $5.0M | $52.5M | ||
| Q2 25 | $-1.7M | $69.6M | ||
| Q1 25 | $-3.0M | $19.5M | ||
| Q4 24 | $275.0K | $65.3M | ||
| Q3 24 | $3.8M | $38.0M | ||
| Q2 24 | $-4.5M | $57.9M | ||
| Q1 24 | $-1.9M | $24.5M |
FCFマージンANIKMMSI
| Q4 25 | 13.0% | 18.8% | ||
| Q3 25 | 17.9% | 13.7% | ||
| Q2 25 | -5.9% | 18.2% | ||
| Q1 25 | -11.3% | 5.5% | ||
| Q4 24 | 0.9% | 18.4% | ||
| Q3 24 | 12.9% | 11.2% | ||
| Q2 24 | -14.6% | 17.1% | ||
| Q1 24 | -6.7% | 7.6% |
設備投資強度ANIKMMSI
| Q4 25 | 2.1% | 6.2% | ||
| Q3 25 | 6.8% | 5.8% | ||
| Q2 25 | 5.2% | 3.6% | ||
| Q1 25 | 10.8% | 5.9% | ||
| Q4 24 | 4.3% | 1.0% | ||
| Q3 24 | 4.1% | 2.8% | ||
| Q2 24 | 11.1% | 3.1% | ||
| Q1 24 | 6.2% | 3.6% |
キャッシュ転換率ANIKMMSI
| Q4 25 | 15.88× | 2.59× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | — | 1.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
